Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.

Drögemöller BI, Brooks B, Critchley C, Monzon JG, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Hayden MR, Gelmon KA, Carleton BC, Ross CJD.

Clin Cancer Res. 2018 Jan 22. doi: 10.1158/1078-0432.CCR-17-2810. [Epub ahead of print]


The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value.

Ezeife DA, Parimi S, Cusano ER, Smith MK, Truong TH, Raissouni S, Lin Y, Monzon JG, Li H, Tam VC, Tang PA.

J Natl Compr Canc Netw. 2017 Aug;15(8):1005-1013. doi: 10.6004/jnccn.2017.0137.


Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC.

JAMA Oncol. 2017 Nov 1;3(11):1558-1562. doi: 10.1001/jamaoncol.2017.0502.


Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.

Lee JW, Pussegoda K, Rassekh SR, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC; CPNDS Clinical Recommendations Group.

Ther Drug Monit. 2016 Aug;38(4):423-31. doi: 10.1097/FTD.0000000000000298. Review.


Predictors of Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer: A Multicenter Study.

Armstrong D, Raissouni S, Price Hiller J, Mercer J, Powell E, MacLean A, Jiang M, Doll C, Goodwin R, Batuyong E, Zhou K, Monzon JG, Tang PA, Heng DY, Cheung WY, Vickers MM.

Clin Colorectal Cancer. 2015 Dec;14(4):291-5. doi: 10.1016/j.clcc.2015.06.001. Epub 2015 Jun 18.


Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.

Monzon JG, Hay AE, McDonald GT, Pater JL, Meyer RM, Chen E, Chen BE, Dancey JE.

Eur J Cancer. 2015 Nov;51(17):2501-7. doi: 10.1016/j.ejca.2015.08.004. Epub 2015 Aug 31.


A phase 2 study of tremelimumab in patients with advanced uveal melanoma.

Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T.

Melanoma Res. 2015 Aug;25(4):342-7. doi: 10.1097/CMR.0000000000000175.


Management of metastatic kidney cancer in the era of personalized medicine.

Monzon JG, Heng DY.

Crit Rev Clin Lab Sci. 2014 Apr;51(2):85-97. doi: 10.3109/10408363.2013.869544. Epub 2014 Jan 22. Review.


Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials.

Freeman GA, Kimmelman J, Dancey J, Monzon JG.

Br J Cancer. 2013 Aug 20;109(4):897-908. doi: 10.1038/bjc.2013.417. Epub 2013 Jul 25.


Targeted agents for the treatment of metastatic melanoma.

Monzon JG, Dancey J.

Onco Targets Ther. 2012;5:31-46. doi: 10.2147/OTT.S21259. Epub 2012 Mar 5.


Retinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literature.

Monzon JG, Hammad N, Stevens SD, Dancey J.

Oncologist. 2012;17(3):384-7. doi: 10.1634/theoncologist.2011-0324. Epub 2012 Feb 14.


Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer.

Monzon JG, Cremin C, Armstrong L, Nuk J, Young S, Horsman DE, Garbutt K, Bajdik CD, Gill S.

Int J Cancer. 2010 Feb 15;126(4):930-9. doi: 10.1002/ijc.24808.

Supplemental Content

Loading ...
Support Center